Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis—A review
- 1 October 2015
- journal article
- research article
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 9 (4) , 223-229
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Use of Antidiabetic Drugs in the U.S., 2003–2012Diabetes Care, 2014
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal AntibodyEndocrinology, 2014
- A multiplex cytokine score for the prediction of disease severity in pediatric hematology/oncology patients with septic shockCytokine, 2013
- Prediction of mortality and macrovascular complications in type 2 diabetes: validation of the UKPDS Outcomes Model in the Casale Monferrato Survey, ItalyDiabetologia, 2013
- Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetesDiabetes, Metabolic Syndrome and Obesity, 2013
- Recent Advances on the Role of Cytokines in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- DPP-4 InhibitorsDiabetes Care, 2011
- Inflammation in AtherosclerosisJACC, 2009
- Long-Term Treatment With Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker RatDiabetes, 2002
- CD26: A Multifunctional Integral Membrane and Secreted Protein of Activated LymphocytesScandinavian Journal of Immunology, 2001